Lee Hwa Young, Kang Sung-Yoon, Kim Kyunghoon, Kim Ju Hee, Ryu Gwanghui, Min Jin-Young, Park Kyung Hee, Park So-Young, Sung Myongsoon, Lee Youngsoo, Yang Eun-Ae, Jee Hye Mi, Ha Eun Kyo, Shin Yoo Seob, Lee Yong Won, Chung Eun Hee, Choi Sun Hee, Koh Young-Il, Kim Seon Tae, Nahm Dong-Ho, Park Jung Won, Shim Jung Yeon, Han Doo Hee, Han Man Yong, Lee Sang Min, Choi Jeong-Hee
Department of Internal Medicine, Seoul St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Division of Pulmonology and Allergy, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
Allergy Asthma Immunol Res. 2025 Mar;17(2):271-284. doi: 10.4168/aair.2025.17.2.271.
This study aimed to identify recent changes of AIT treatment behaviors in real-world clinical practice using a questionnaire survey in Korea. The questionnaire on AIT prescriptions and practical experiences was distributed to all members of the Korean Academy of Asthma Allergy and Clinical Immunology in June 2022. The responses were analyzed and compared with the results from 2009 and 2017. In total, 115 responses (10.1%) were collected; 58 (50.4%) from internal medicine, 34 (29.6%) from pediatricians, and 21 (18.3%) from otolaryngologists. The prescription rate for subcutaneous immunotherapy (SCIT) was 53.8%, showing a decrease from those in 2009 and 2017; however, that for sublingual immunotherapy (SLIT) increased steadily, reaching 17.9% in 2009, 40.3% in 2017, and 46.2% in 2022. The prescription rates for asthma and atopic dermatitis increased by 4.6% and 7.9%, respectively. The most frequently prescribed allergens for SCIT in 2022 were house dust mites (32.9%), pollen (30.6%), and animal dander (28.2%), with the rate for animal dander showing a significant increase from 10.3% in 2009. Most physicians (93%) used mixed allergens for SCIT, with 42.8% using a combination of 5 or more allergens. Fifty-eight (67.4%) respondents reported cases of anaphylaxis during SCIT and 36.2% reported systemic adverse reactions during SLIT. In conclusion, SLIT prescriptions, AIT for asthma and atopic dermatitis, and AIT with animal dander increased significantly from 2009 to 2022. Serial surveys of AIT practices are helpful in identifying the changes of real-world clinical practice of AIT.
本研究旨在通过在韩国进行问卷调查，确定在现实临床实践中变应性免疫疗法（AIT）治疗行为的近期变化。2022年6月，关于AIT处方和实践经验的问卷被分发给了韩国哮喘、过敏与临床免疫学会的所有成员。对回复进行了分析，并与2009年和2017年的结果进行了比较。总共收集到115份回复（10.1%）；其中58份（50.4%）来自内科医生，34份（29.6%）来自儿科医生，21份（18.3%）来自耳鼻喉科医生。皮下免疫疗法（SCIT）的处方率为53.8%，与2009年和2017年相比有所下降；然而，舌下免疫疗法（SLIT）的处方率稳步上升，2009年达到17.9%，2017年为40.3%，2022年为46.2%。哮喘和特应性皮炎的处方率分别上升了4.6%和7.9%。2022年SCIT最常处方的变应原是屋尘螨（32.9%）、花粉（30.6%）和动物皮屑（28.2%），动物皮屑的处方率从2009年的10.3%显著上升。大多数医生（93%）在SCIT中使用混合变应原，42.8%的医生使用5种或更多变应原的组合。58名（67.4%）受访者报告了SCIT期间的过敏反应病例，36.2%的受访者报告了SLIT期间的全身不良反应。总之，从2009年到2022年，SLIT处方、针对哮喘和特应性皮炎的AIT以及含动物皮屑的AIT显著增加。对AIT实践进行系列调查有助于确定AIT现实临床实践中的变化。
